Jennifer Young Pierce

Jennifer Young Pierce, M.D., M.P.H., F.A.C.O.G.

Gynecologic OncologistResidency Program Director for Obstetrics and Gynecology; Leader of Cancer Control and Prevention; Professor of Interdisciplinary Clinical OncologySpecialty: Cancer Care

Refer a Patient

Request an Appointment

Or call to make an appointment1 (251) 665-8000

Share this provider with a friend or family

About Jennifer Young Pierce, M.D.

Dr. Jennifer Y. Pierce was recruited to MCI from the Medical University of South Carolina, where she served as GYN Oncology Disease Team Leader at Hollings Cancer Center and Associate Professor in Obstetrics and Gynecology. With a degree in medicine from MUSC and degrees in engineering and public health from the University of Virginia – Charlottesville, Dr. Pierce became the first female gynecologic oncologist in South Carolina in 2009. Dr. Pierce serves on the National HPV Roundtable as well as on the cervical cancer and immunotherapy committees for the NRG, the cooperative clinical trials group of the NCI. Dr. Pierce treats patients suffering from gynecologic malignancies, including all medical and surgical aspects.

View a full list of Dr. Pierce's research papers at the National Library of Medicine.

Conditions Treated

Cervical Cancer
Endometrial Cancer
Ovarian Cancer
Uterine Cancer
Vaginal Cancer
Vulvar Cancer

Professional Memberships

Alabama American College of Obstetricians and Gynecologists
American College of Obstetricians and Gynecologists (ACOG), Fellow
NRG (fusion of NSABP, GOG, and RTOG)
Society of Gynecologic Oncology, Fellow
South Atlantic Association of Obstetricians and Gynecologists

Board Certifications

American Board of Obstetrics and Gynecology (Obstetrics and Gynecology)
American Board of Obstetrics and Gynecology (Gynecologic Oncology)

Education

Graduate School (Public Health): University of Virginia Health System | Charlottesville, VA
Medical School: Medical University of South Carolina | Charleston, SC
Residency: Brigham and Women's Hospital - Massachusetts General Hospital Harvard University | Boston, MA
Fellowship: University of Virginia Health System | Charlottesville, VA

Research Interests

Screening and treatment of pre-invasive and invasive vulvar, vaginal, and cervical cancers
Additional HPV-related diseases

Languages

English

Locations

Mitchell Cancer Institute
1660 Spring Hill Avenue Mobile, Alabama 36604
(251) 665-8000
Learn More Plan a Visit

Clinical Trials

19-004 - Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001)Status: open

A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma (LEAP-001)

Patients with Endometrial Carcinoma

Mitchell Cancer Institute

1660 Spring Hill Avenue Mobile, Alabama 36604

20-332 - GOG-3039 - A Phase II Study of Abemaciclib in Combination with Letrozole in Advanced, Recurrent or Metastatic Endometrioid Endometrial CancerStatus: open

Abemaciclib and Letrozole to Treat Endometrial Cancer

Patients with Endometrial Carcinoma

Mitchell Cancer Institute

1660 Spring Hill Avenue Mobile, Alabama 36604

19-362 - Safety and Pharmacokinetics Study of MK-5890 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001)Status: open

A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors

Treatment for Advanced Solid Tumors

Mitchell Cancer Institute

1660 Spring Hill Avenue Mobile, Alabama 36604

18-325 - A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid TumorsStatus: open

A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors

Treatment for Solid Tumors

Mitchell Cancer Institute

1660 Spring Hill Avenue Mobile, Alabama 36604

19-255 - Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical CancerStatus: open

A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (anti–PD-1) as a Monotherapy or Combination Therapy with AGEN1884 (anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer (Second Line) - RaPiDS

Treatment for Cervical Cancer

Mitchell Cancer Institute

1660 Spring Hill Avenue Mobile, Alabama 36604

19-247 - Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical CancerStatus: open

A Phase II Study of Cabozantinib (XL184) Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer

Treatment for Cervical Cancer

Mitchell Cancer Institute

1660 Spring Hill Avenue Mobile, Alabama 36604

21-056 - Study of AVB-S6-500 in Combination With Paclitaxel vs Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian CancerStatus: open

A Phase 3, Randomized, Double-Blind, Adaptive, Placebo/Paclitaxel-Controlled Study of AVB-S6-500 in Combination with Paclitaxel in Patients with Platinum-Resistant Recurrent Ovarian Cancer

Treatment for Ovarian Cancer

Mitchell Cancer Institute

1660 Spring Hill Avenue Mobile, Alabama 36604

19-077 - Radiation Therapy and Cisplatin With or Without Triapine in Treating Patients With Newly Diagnosed Stage IB2, II, or IIIB-IVA Cervical Cancer or Stage II-IVA Vaginal CancerStatus: open

A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer.

Treatment for Uterine / Vaginal Cancer

Mitchell Cancer Institute

1660 Spring Hill Avenue Mobile, Alabama 36604

Related News

Gyn onc fellowship

Education | General News

USA Health creates gynecologic oncology fellowship program

The three-year fellowship, one of 61 in the United States, significantly will improve access to gynecologic cancer care for women in Alabama.

Posted 1 month agoRead Story >

Jennifer Young Pierce 200608 203100

Pierce named OB-GYN residency program director at USA Health

As director, Pierce says she fulfills the roles of principal, counselor, recruiter, financial officer, time keeper and registrar for 16 physicians in training.

Posted 11 months agoRead Story >

Jennifer Pierce

Pierce selected for ASCO Leadership Development Program

Dr. Jennifer Young Pierce, professor of Interdisciplinary Clinical Oncology and leader of Cancer Control and Prevention at USA Health Mitchell Cancer Institute, is one of 16 oncologists to be chosen for a leadership development program by the American Society of Clinical Oncology.

Posted 1 year agoRead Story >

Jennifer Pierce

HPV-related cancer rates affect vaccine uptake in Alabama, study says

USA Health researchers studying HPV vaccination rates in Alabama discovered that counties with higher rates of HPV-related cancers in unvaccinated adults had higher rates of HPV vaccinations among adolescents, according to research presented at the Society of Gynecologic Oncology’s Annual Meeting on Women’s Cancer.

Posted 2 years agoRead Story >

GO Teal and White Campaign

Healthy Living | Disease Prevention

GO Teal and White Campaign to Raise Awareness About Cervical Cancer

USA Health Mitchell Cancer Institute has launched a statewide campaign called “GO Teal and White” to raise awareness about how to prevent cervical cancer, which is killing more women in Alabama than in any other state in the nation. The campaign will run throughout January, Cervical Cancer Awareness Month.

Posted 2 years agoRead Story >